Leash Bio

Leash Bio is transforming drug design by building a massive, proprietary dataset of protein-molecule interactions. The company has measured over 30 billion interactions by screening millions of compounds against thousands of proteins. This rich dataset is ideal for training advanced machine learning models to rapidly identify new drug candidates. Central to their technology is a dynamic, cyclical engine that continuously harnesses data, iterates machine learning, and refines molecular designs, with each cycle taking only a few months. They have already made and tested 6.7 million ML-designed molecules. Leash Bio is initially focusing on two internal oncology targets and working with biopharma partners to explore new molecule opportunities.

Key Benefits

• Massive proprietary dataset of 30B+ protein-molecule interactions
• Rapid ML-driven design cycles (months per iteration)
• Scalable software for novel molecule design
• Partnerships with biopharma for efficient exploration